Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) Sees Large Decrease in Short Interest

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTHGet Rating) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 3,200 shares, a decline of 20.0% from the August 15th total of 4,000 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Anthera Pharmaceuticals Price Performance

Anthera Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.00.

About Anthera Pharmaceuticals

(Get Rating)

Anthera Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.

See Also

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.